bruceine a has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choonong, R; Churod, T; Juengwatanatrakul, T; Juntarapornchai, S; Kanchanapoom, T; Ketsuwan, K; Kitisripanya, T; Komaikul, J; Masrinoul, P; Palabodeewat, S; Punyahathaikul, S; Putalun, W; Ruangdachsuwan, S; Yusakul, G | 1 |
| Andino, R; Bonser, LR; Chung, CI; Erle, DJ; Garcia-Knight, MA; Ghias, K; Hargett, KL; Jackson, PK; Lee, IT; Li, X; Lidsky, PV; Nakayama, T; Nayak, JV; Peng, S; Shoichet, BK; Shu, X; Tassetto, M; Wu, CT; Xiao, Y; Yang, J | 1 |
2 other study(ies) available for bruceine a and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Evaluating the
Topics: Antiviral Agents; Common Cold; Coronavirus OC43, Human; COVID-19; Eurycoma; Humans; Plants; Quassins; SARS-CoV-2 | 2022 |
Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2.
Topics: Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; Humans; Mice; Peptidyl-Dipeptidase A; SARS-CoV-2; Vero Cells | 2023 |